DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2dlz6n/investigation) has announced the addition of the "Investigation Report on China Imatinib Market, 2009-2018" report to their offering.
Imatinib is originally developed by Novartis with the trade name ""Gleevec"". It was approved to the U.S.A. to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) blastic phase, accelerated phase or patients in chronic phase after a-interferon failure. In November 2001 it was approved in Europe and to Chinese market in April 2002. Average survival time of CML patients used to be 3 to 6 years before imatinib was developed. Due to its revolutionary treatment, imatinib prolongs 85% to 90% CML patients' life by 10 years. With much less side effects, imatinib is significantly safer than interferon. As a result, it became a first-line drug in CML treatment soon.
In 2002 imatinib gained accelerated approval from FDA to be the first-line drug in advanced or metastatic gastrointestinal stromal tumors (GIST) treatment. As a first-line drug in clinical treatment, the sales revenue of imatinib exceeded USD 1 billion in 2003 and it is still increasing rapidly.
Imatinib acquired its first indication approval in 2001 and has since then acquired 10 indication approvals. Increasing number of indications is also one of the main factors making imatinib a blockbuster drug.
Imatinib was approved to China in 2002 to treat CML and GIST. Its market size keeps increasing after its launch. According to CRI's investigation on sample hospital market, the CAGR of its sales revenue exceeded 40% from 2005 to 2012. It is estimated that growth of original drugs will slow down because of launched generic drugs.
As an orphan drug approved to the market, imatinib becomes a blockbuster drug mainly due to the successful marketing strategy. Considered as a specific drug to treat rare diseases (CML and GIST), Gleevec makes a marketing strategy to launch drug donation charity program through negotiation with medicare institutes. The program allows patients to take the drug for free after the donation so as to increase patients' dependence on the drug. This gesture has not only solved patients' problems but also brought excellent reputation for Gleevec, making its global sales revenue surge.
Key Topics Covered:
1 Relevant Concepts of Imatinib
2 Market Overview of Imatinib in China, 2010-2013
3 Investigation on Sales Value of Imatinib in China, 2010-2013
4 Investigation on Market Share of Major Imatinib Manufacturers in China, 2010-2013
5 Investigation on Market Size of Imatinib by Dosage Form in China, 2010-2013
6 Reference Price of Imatinib Produced by Different Enterprises in China Hospital Market, 2014
7 Major Manufacturing Enterprises in China Imatinib Market, 2009-2014
8 Prospect of China Imatinib Market, 2014-2018
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Hansoh Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/2dlz6n/investigation